Europe Vaccines Market to 2027 - By Size, Share, Growth by End User and Forecast| Business Market Insights

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Vaccines Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Vaccines Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Increasing prevalence of infectious diseases
5.1.3 Rising geriatric population
5.1.4 Government initiatives and funding
5.1.5 Technological advancements
5.1.6 Increasing healthcare expenditure
5.1.7 Growing awareness about vaccination

5.2 Market Opportunities

5.2.1
5.2.2 Emerging markets with high disease burden
5.2.3 Development of novel vaccine technologies
5.2.4 Increasing demand for combination vaccines
5.2.5 Rising focus on personalized medicine
5.2.6 Growing pipeline of vaccine candidates
5.2.7 Expanding distribution channels and supply chain networks

5.3 Future Trends

5.3.1
5.3.2 Increasing focus on mRNA and DNA vaccines
5.3.3 Advancements in vaccine delivery systems
5.3.4 Development of thermostable vaccines
5.3.5 Rising demand for self-administered vaccines
5.3.6 Integration of AI and machine learning in vaccine development
5.3.7 Growing importance of digital health in vaccine distribution and tracking

5.4 Impact of Drivers and Restraints

6. Europe Vaccines Market Regional Analysis

6.1 Europe Vaccines Market Overview

6.2 Europe Vaccines Market Revenue 2016-2027 (US$ Million)

6.3 Europe Vaccines Market Forecast Analysis

7. Europe Vaccines Market Analysis – by Technology

7.1 Recombinant Vaccines

7.1.1 Overview
7.1.2 Recombinant Vaccines: Europe Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Conjugate Vaccines

7.2.1 Overview
7.2.2 Conjugate Vaccines: Europe Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Live Attenuated Vaccines

7.3.1 Overview
7.3.2 Live Attenuated Vaccines: Europe Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Inactivated and Subunit Vaccines

7.4.1 Overview
7.4.2 Inactivated and Subunit Vaccines: Europe Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Toxoid Vaccines

7.5.1 Overview
7.5.2 Toxoid Vaccines: Europe Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Vaccines Market Analysis – by Disease Indication

8.1 DTP

8.1.1 Overview
8.1.2 DTP: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Influenza

8.2.1 Overview
8.2.2 Influenza: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Hepatitis

8.3.1 Overview
8.3.2 Hepatitis: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Respiratory Syncytial Virus

8.4.1 Overview
8.4.2 Respiratory Syncytial Virus: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

8.5 Other Diseases

8.5.1 Overview
8.5.2 Other Diseases: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe Vaccines Market Analysis – by Route of Administration

9.1 Oral

9.1.1 Overview
9.1.2 Other Diseases: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Injectable

9.2.1 Overview
9.2.2 Other Diseases: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Other Routes of Administration

9.3.1 Overview
9.3.2 Other Diseases: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe Vaccines Market – Europe Analysis

10.1 Europe

10.1.1 Europe Vaccines Market Breakdown, by Key Country, 2019 and 2027 (%)
10.1.1.1 Europe Vaccines Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 UK: Europe Vaccines Market Breakdown, by Technology
10.1.1.1.2 UK: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.1.3 UK: Europe Vaccines Market Breakdown, by Route of Administration

10.1.1.2 Germany: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Germany: Europe Vaccines Market Breakdown, by Technology
10.1.1.2.2 Germany: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.2.3 Germany: Europe Vaccines Market Breakdown, by Route of Administration

10.1.1.3 France: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 France: Europe Vaccines Market Breakdown, by Technology
10.1.1.3.2 France: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.3.3 France: Europe Vaccines Market Breakdown, by Route of Administration

10.1.1.4 Russia: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Russia: Europe Vaccines Market Breakdown, by Technology
10.1.1.4.2 Russia: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.4.3 Russia: Europe Vaccines Market Breakdown, by Route of Administration

10.1.1.5 Italy: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.5.1 Italy: Europe Vaccines Market Breakdown, by Technology
10.1.1.5.2 Italy: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.5.3 Italy: Europe Vaccines Market Breakdown, by Route of Administration

10.1.1.6 Rest of Europe: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Vaccines Market Breakdown, by Technology
10.1.1.6.2 Rest of Europe: Europe Vaccines Market Breakdown, by Disease Indication
10.1.1.6.3 Rest of Europe: Europe Vaccines Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Vaccines Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 PFIZER INC

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 GlaxoSmithKline plc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Merck & Co., Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Sanofi

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Johnson & Johnson Services, Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Panacea Biotec Limited

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Astellas Pharma Inc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 NOVAVAX, INC.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 VBI Vaccines Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Bavarian Nordic

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights